Patents Examined by Karen E. Brown
  • Patent number: 5714334
    Abstract: The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG. The invention also pertains to methods for detecting IgA.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: February 3, 1998
    Assignee: Medical College of Ohio
    Inventor: Ervin Faulmann
  • Patent number: 5702917
    Abstract: DNA sequences encoding a novel intercellular adhesion molecule polypeptide (designated "ICAM-4") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 30, 1997
    Assignee: ICOS Corporation
    Inventors: Patrick D. Kilgannon, W. Michael Gallatin
  • Patent number: 5700658
    Abstract: DNA sequences encoding a novel intercellular adhesion molecule polypeptide (designated "ICAM-4") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures.
    Type: Grant
    Filed: May 18, 1994
    Date of Patent: December 23, 1997
    Assignee: ICOS Corporation
    Inventors: Patrick D. Kilgannon, W. Michael Gallatin
  • Patent number: 5700907
    Abstract: The present invention relates to new nucleotide sequences coding for variable regions of .beta. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: December 23, 1997
    Assignee: Roussel Uclaf
    Inventors: Thierry Hercend, Frederic Triebel, Sergio Roman-Roman, Laurent Ferradini
  • Patent number: 5690928
    Abstract: Methods and compositions for treating bladder cancer using TGF-alpha or EGF fused to PE.sub.40 or cysteine modified derivatives are taught. Also, a method of producing TGF-alpha-PE.sub.40 derivatives of enhanced potency is described.
    Type: Grant
    Filed: April 11, 1994
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David C. Heimbrook, Allen I. Oliff, Steven M. Stirdivant, Janet Ahern
  • Patent number: 5686408
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: November 11, 1997
    Assignee: The Beth Israel Hospital Association
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
  • Patent number: 5679546
    Abstract: The present invention relates to novel chimeric proteins comprising a first polypeptide which inhibits complement activation, linked to a second polypeptide which inhibits complement activation, nucleic acids encoding novel chimeric proteins and methods of reducing inflammation with the administration of the chimeric proteins of the invention.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: October 21, 1997
    Assignee: Cytomed, Inc.
    Inventors: Jone-Long Ko, C. Grace Yeh
  • Patent number: 5670342
    Abstract: Novel peptides are described which are biologically active derivatives of the EGF-like domain of NDF/heregulins and which stimulate the proliferation and differentiation of colon epithelial cells and support the survival and growth of Schwann cells.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: September 23, 1997
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • Patent number: 5663293
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: September 2, 1997
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • Patent number: 5663300
    Abstract: Polynucleotide sequences encoding novel cadherin-related polypeptides, designated protocadherins, and variants thereof are provided by the invention as well as methods and materials for the recombinant production of the same. Antibody substances specific for protocadherins are also disclosed as useful for modulating the natural binding and/or regulatory activities of the protocadherins.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 2, 1997
    Assignee: Doheny Eye Institute
    Inventor: Shintaro Suzuki
  • Patent number: 5661005
    Abstract: .beta..sub.3 integrin subunit specific polypeptides, cDNAs which encode these polypeptides and methods of producing these polypeptides are provided.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: August 26, 1997
    Assignees: Trustees of the University of Pennsylvania, Scripps Research Institute
    Inventors: Sanford Shattil, Timothy O'Toole, Mark Ginsberg
  • Patent number: 5658877
    Abstract: Pharmaceutical compositions containing safe and effective amounts of Annexin I or 33 kDa(PLBP) can be used in a number of methods for the benefit of animals.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: August 19, 1997
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Francis H. C. Tsao
  • Patent number: 5654267
    Abstract: The present invention provides compositions and methods for promoting cell migration and tissue regeneration. The composition contains a ligand for the .alpha..sub.v .beta..sub.3 integrin and a ligand for the insulin receptor, the PDGF receptor, the IL-4 receptor, or the IGF receptor, combined in a matrix. The combination of .alpha..sub.v .beta..sub.3 ligand and growth factor produces an unexpected synergistic effect in enhancing wound healing compared with the effect of each component separately. The present invention also provides a method of wound healing and a method of inducing tissue regeneration by applying the compositions of the present invention to the site of the wound.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: August 5, 1997
    Assignee: La Jolla Cancer Research Center
    Inventors: Kristiina Vuori, Erkki I. Ruoslahti
  • Patent number: 5652343
    Abstract: The invention relates to glycoprotein ligands of selectins. The invention further relates to methods and means for preparing and to nucleic acids encoding these ligands. The invention further concerns a method of treating a symptom or condition associated with excessive binding of circulating leukocytes to endothelial cells by administering to a patient in need of such treatment a glycoprotein ligand of a selectin.
    Type: Grant
    Filed: August 23, 1994
    Date of Patent: July 29, 1997
    Assignees: Genentech, Inc., The Regents of the University of California
    Inventors: Laurence A. Lasky, Yasuyuki Imai, Steven D. Rosen, Mark S. Singer
  • Patent number: 5648332
    Abstract: A soluble T-cell receptor .alpha.-chain produced by suppressor T-cell. The said soluble T-cell receptor .alpha.-chain is useful as a prophylactic and therapeutic agent for autoimmune diseases generated to a wide variety of autoantigens irrespective of specificity to the said suppressor T-cell.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: July 15, 1997
    Assignee: Hoechst Japan Limited
    Inventors: Hiroshi Watanabe, Nobuyuki Yamagata, Masaru Taniguchi
  • Patent number: 5644030
    Abstract: The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: July 1, 1997
    Assignee: Medical College of Ohio
    Inventor: Ervin Faulmann
  • Patent number: 5643749
    Abstract: New forms of interferon .alpha.-receptors are provided. They may be prepared recombinantly and may be used in diagnosis and therapy.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: July 1, 1997
    Assignee: Yeda Research and Development Co, Ltd.
    Inventors: Michel Revel, Carolina Abramovich, Edward Ratovitski
  • Patent number: 5641743
    Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps. The growth factors may be useful in the promotion of angiogenesis, such as in the promotion of wound healing, bone healing and in the treatment of burns, as well as in promoting the formation, maintenance and repair of tissue, in particular, neural tissue.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: June 24, 1997
    Assignee: American Cyanamid Company
    Inventors: Peter Bohlen, Peter Gautschi-Sova
  • Patent number: 5637567
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: June 10, 1997
    Assignee: The Beth Israel Hospital Association
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
  • Patent number: 5633147
    Abstract: Disclosed is a human TGF.alpha.-H1 polypeptide and DNA (RNA) encoding such TGF.alpha.-H1 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and for producing antibodies and antagonists against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects against various diseases. Also provided, are methods of using the antibodies and antagonists to inhibit TGF.alpha.-H1 for therapeutic purposes.
    Type: Grant
    Filed: March 8, 1994
    Date of Patent: May 27, 1997
    Assignee: Human Genome Sciences, Inc.
    Inventors: Paul S. Meissner, Rebecca A. Fuldner, Mark D. Adams